ATLANTA, GA – – (ACCESSWIRE – November 9, 2022) – – Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Eiger BioPharmaceuticals, Inc. (“Eiger BioPharmaceuticals” or the “Company”) (NASDAQ: EIGR). The lawsuit alleges Eiger BioPharmaceuticals made materially false and misleading statements and/or failed to disclose adverse facts about the Company’s business, operations, and compliance policies, including: (i) Defendants overstated the Company’s clinical and regulatory drug development expertise; (ii) Defendants failed to properly assess, and/or ignored issues with, the design of the Company’s TOGETHER study and its ability to support an Emergency Use Authorization (“EUA”) for its COVID-19 therapy; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for its therapy’s EUA in the current context of the pandemic; (iv) thus, the FDA was unlikely to approve an EUA; (v) as a result, the therapy’s regulatory and commercial prospects were overstated.
If you bought shares of Eiger BioPharmaceuticals between March 10, 2021 and October 4, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at here to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is January 9, 2022.
Lead Plaintiff Deadline Has Passed
January 9, 2023